Recombinant Human RGS17 Protein, N-His from ProteoGenix; catalogue ARO-P11762; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Title: Introduction to Recombinant Human RGS17 Protein
Recombinant Human RGS17 Protein, also known as Regulator of G protein signaling 17, is a highly conserved protein that plays a crucial role in regulating the activity of G protein-coupled receptors (GPCRs). This protein is encoded by the RGS17 gene and is expressed in various tissues including brain, heart, and kidney. Recombinant Human RGS17 Protein is widely used in research and pharmaceutical applications due to its unique structure and function.
Title: Structure of Recombinant Human RGS17 Protein
Recombinant Human RGS17 Protein is a 30 kDa protein consisting of 261 amino acids. It contains a conserved RGS domain, which is responsible for its regulatory function. This domain is composed of approximately 120 amino acids and is highly conserved among different species. The RGS domain of Recombinant Human RGS17 Protein interacts with the G protein alpha subunit and acts as a GTPase-activating protein (GAP), promoting the hydrolysis of GTP to GDP and thereby terminating the signaling activity of GPCRs.
Title: Activity of Recombinant Human RGS17 Protein
The main function of Recombinant Human RGS17 Protein is to regulate the activity of GPCRs, which are involved in various physiological processes such as vision, taste, and hormone signaling. GPCRs are activated by binding to specific ligands, which triggers a cascade of signaling events. However, prolonged activation of GPCRs can lead to abnormal signaling and contribute to various diseases. Recombinant Human RGS17 Protein acts as a negative regulator of GPCR signaling by accelerating the hydrolysis of GTP and promoting the inactivation of G proteins.
Title: Applications of Recombinant Human RGS17 Protein
Recombinant Human RGS17 Protein has a wide range of applications in both basic research and drug discovery. Due to its role in regulating GPCR signaling, this protein is used in studies related to vision, taste, and hormone signaling. It is also used in drug discovery to screen for potential therapeutics that target GPCRs. In addition, Recombinant Human RGS17 Protein has been implicated in various diseases such as cancer, cardiovascular diseases, and neurological disorders. Therefore, it is a potential target for the development of novel therapeutics.
Title: Production of Recombinant Human RGS17 Protein
Recombinant Human RGS17 Protein is produced using recombinant DNA technology. The RGS17 gene is cloned into an expression vector and then introduced into a suitable host cell, such as E. coli or mammalian cells. The host cells are then cultured and induced to produce large quantities of the protein. The recombinant protein is then purified using various chromatography techniques to obtain a highly pure and active form of Recombinant Human RGS17 Protein.
Title: Antigenicity of Recombinant Human RGS17 Protein
Recombinant Human RGS17 Protein is an antigen, meaning it can induce an immune response in the body. This property makes it a valuable tool in immunological studies and vaccine development. The RGS domain of Recombinant Human RGS17 Protein is highly conserved among different species, making it an ideal antigen for cross-reactivity studies. In addition, the recombinant protein can be used to generate specific antibodies that can be used for detection and quantification of RGS17 in various biological samples.
In conclusion, Recombinant Human RGS17 Protein is a crucial regulator of GPCR signaling and has a wide range of applications in research and drug discovery. Its unique structure and activity make it an important tool in understanding the complex signaling pathways involved in various physiological processes and diseases. With ongoing research, Recombinant Human RGS17 Protein holds great potential for the development of novel therapeutics for various diseases.
ProteoGenix catalogue number ARO-P11762. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 18.49 kDa; Fragment: Thr74-Ser210; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
